It appears that improved access to timely anti-retroviral treatment (ART) is driving down TB-HIV trends as HIV management in Ethiopia has shifted from providing ART to only stage 3 and 4 HIV patients or those with CD4 count < 200 cells/mm3 to all HIV patients irrespective of stage and CD4 count. This evidence concerns the gene CD4 and tuberculosis.